• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques .

作者信息

D'Silva Kristin M, Serling-Boyd Naomi, Wallwork Rachel, Hsu Tiffany Y-T, Sparks Jeffrey A, Wallace Zachary Scott

机构信息

Division of Rheumatology, Allergy, and Immunology, Harvard Medical School, Boston, Massachusetts, USA.

Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.

出版信息

Ann Rheum Dis. 2022 Aug;81(8):e135. doi: 10.1136/annrheumdis-2020-218431. Epub 2020 Jul 13.

DOI:10.1136/annrheumdis-2020-218431
PMID:32660976
Abstract
摘要

相似文献

1
Response to: 'COVID-19 in patients with rheumatic diseases: what is the real mortality risk?' by Marques .对马克斯所著《风湿性疾病患者的COVID-19：真正的死亡风险是什么？》的回应
Ann Rheum Dis. 2022 Aug;81(8):e135. doi: 10.1136/annrheumdis-2020-218431. Epub 2020 Jul 13.
2
Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco . Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases.关于吉安弗兰切斯科所著《风湿性疾病患者新冠病毒肺炎住院相关特征：来自新冠病毒肺炎全球风湿病联盟医生报告登记处的数据》的通信。在风湿性肌肉骨骼疾病患者中，疾病活动度而非糖皮质激素治疗，可能与新冠病毒肺炎的严重程度相关。
Ann Rheum Dis. 2022 Nov;81(11):e222. doi: 10.1136/annrheumdis-2020-218845. Epub 2020 Sep 7.
3
Rheumatic disease and COVID-19: epidemiology and outcomes.风湿性疾病与2019冠状病毒病：流行病学与结局
Nat Rev Rheumatol. 2021 Feb;17(2):71-72. doi: 10.1038/s41584-020-00562-2.
4
Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'.关于“自身免疫性炎性风湿病患者中与 COVID-19 相关的住院风险因素”的通信
Ann Rheum Dis. 2023 Mar;82(3):e69. doi: 10.1136/annrheumdis-2020-219542. Epub 2020 Dec 18.
5
COVID-19 in Rheumatic Diseases: A Research Agenda.风湿性疾病中的新型冠状病毒肺炎：一项研究议程。
Arthritis Rheumatol. 2020 Oct;72(10):1596-1599. doi: 10.1002/art.41447. Epub 2020 Sep 22.
6
SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease.风湿性疾病患者感染新冠病毒后对严重急性呼吸综合征冠状病毒2的抗体反应。
Ann Rheum Dis. 2021 Jun;80(6):817-819. doi: 10.1136/annrheumdis-2020-219808. Epub 2021 Jan 12.
7
Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs' by Conticini .风湿性疾病患者中新型冠状病毒肺炎（COVID-19）的患病率：需要等待大型合作研究的结果。对Conticini所著《一大群接受生物和靶向合成抗风湿药物治疗的患者中的COVID-19肺炎》的回应
Ann Rheum Dis. 2021 Feb;80(2):e15. doi: 10.1136/annrheumdis-2020-217738. Epub 2020 May 15.
8
Response to: 'Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors' by Jovani .对乔瓦尼所著《西班牙1037例接受生物制剂和JAK抑制剂治疗的风湿病患者中重症COVID-19的发病率》的回应
Ann Rheum Dis. 2022 Jul;81(7):e132. doi: 10.1136/annrheumdis-2020-218179. Epub 2020 Jun 25.
9
Characteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy.38例接受改善病情抗风湿药治疗的风湿性疾病合并新型冠状病毒肺炎患者的特征与演变
Clin Rheumatol. 2021 Mar;40(3):1197-1199. doi: 10.1007/s10067-020-05510-9. Epub 2020 Nov 24.
10
Factors influencing the course of COVID-19 in the inflammatory rheumatic diseases.影响炎症性风湿性疾病中COVID-19病程的因素。
Clin Exp Rheumatol. 2023 Mar;41(3):758-759. doi: 10.55563/clinexprheumatol/3pcfrz. Epub 2022 Oct 13.